SCHEMBL4351904

SCHEMBL4351904

CC(C)CN(C[C@H]1OC(C)(C)N(C(=O)O)[C@H]1Cc1ccc(OCc2cccc([N+](=O)[O-])c2)cc1)S(=O)(=O)c1ccc2c(c1)OCO2

nearest known ligand 0.44

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
BMP1 P13497 3/20 0.44
MAOB P27338 2/20 0.43
ADAMTS4 O75173 2/20 0.41
MMP13 P45452 2/20 0.41
HTT P42858 2/20 0.40
LMNA P02545 1/20 0.40
FFAR1 O14842 1/20 0.39
MMP2 P08253 2/20 0.38
MMP14 P50281 1/20 0.38
ADAMTS5 Q9UNA0 1/20 0.38
MAOA P21397 1/20 0.38
MMP9 P14780 1/20 0.37
ALDH1A1 P00352 3/20 0.36
ABCB1 P08183 1/20 0.36
MEN1 O00255 1/20 0.36
KMT2A Q03164 1/20 0.36
MEP1B Q16820 1/20 0.36
EDNRA P25101 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4345112 0.94 LMNA (0.40) BMP1ADAMTS4MMP13HTTLMNA
SCHEMBL4347227 0.92 ADAMTS4 (0.46) BMP1MAOBADAMTS4MMP13HTT
SCHEMBL4352479 0.92 MMP13 (0.40) ADAMTS4MMP13HTTLMNAMMP2
SCHEMBL4340203 0.91 MAOB (0.39) MAOBADAMTS4MMP13HTTLMNA
SCHEMBL4353025 0.90 ADAMTS4 (0.40) BMP1MAOBADAMTS4MMP13HTT
SCHEMBL4341082 0.88 LMNA (0.40) BMP1MAOBADAMTS4MMP13HTT
SCHEMBL4347715 0.88 LMNA (0.40) MAOBADAMTS4MMP13HTTLMNA
SCHEMBL4340869 0.87 LMNA (0.40) MAOBADAMTS4MMP13HTTLMNA
SCHEMBL6051075 0.86 ABCB1 (0.49) BMP1MAOBADAMTS4MMP13HTT
SCHEMBL4340851 0.86 MMP2 (0.49) MAOBADAMTS4MMP13MMP2MMP14

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8455497-B2 Inhibitors of aspartyl protease VERTEX PHARMACEUTICALS INCORPORATED (US) 2013-06-04 US disclosed
US-20090274650-A1 INHIBITORS OF ASPARTYL PROTEASE VERTEX PHARMACEUTICALS INCORPORATED 2009-11-05 US disclosed
EP-1194404-B1 INHIBITORS OF ASPARTYL PROTEASE VERTEX PHARMA (US) 2006-05-03 EP disclosed
US-6878728-B1 Inhibitors of aspartyl protease VERTEX PHARMACEUTICAL INCORPORATED (US) 2005-04-12 US disclosed
US-20040122000-A1 Inhibitors of aspartyl protease VERTEX PHARMACEUTICALS INCORPORATED. 2004-06-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040122000-A1 Inhibitors of aspartyl protease SPINT2, DNPEP, PRSS1 BMP1 4692/4885MAOB 4144/4885ADAMTS4 508/4885
US-20090274650-A1 INHIBITORS OF ASPARTYL PROTEASE SPINT2, DNPEP, PRSS1 BMP1 4692/4885MAOB 4144/4885ADAMTS4 508/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.